Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Primary fibromyalgia : clinical parameters in relation to serum procollagen type III aminoterminal peptide. / Jacobsen, S; Jensen, L T; Foldager, M; Danneskiold-Samsøe, B.
In: British Journal of Rheumatology, Vol. 29, No. 3, 06.1990, p. 174-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Primary fibromyalgia
T2 - clinical parameters in relation to serum procollagen type III aminoterminal peptide
AU - Jacobsen, S
AU - Jensen, L T
AU - Foldager, M
AU - Danneskiold-Samsøe, B
PY - 1990/6
Y1 - 1990/6
N2 - Serum concentrations of procollagen type III aminoterminal peptide have previously been reported to be low in some patients with primary fibromyalgia and the aim of this study was to determine if such patients differ clinically from primary fibromyalgia patients with normal levels of procollagen type III aminoterminal peptide. Subjective symptoms, tender points and dynamic muscle strength in 45 women with primary fibromyalgia were related to serum concentrations of procollagen type III aminoterminal peptide. Patients with low serum concentrations of procollagen type III aminoterminal peptide had more symptoms, a higher frequency of tender points and lesser quality of sleep compared to patients with normal serum concentrations of procollagen type III aminoterminal peptide (P less than 0.05). They also had a lower dynamic muscle strength (P less than 0.0005). We conclude that the serum concentrations of procollagen type III aminoterminal peptide of primary fibromyalgia patients are connected to the disease impact.
AB - Serum concentrations of procollagen type III aminoterminal peptide have previously been reported to be low in some patients with primary fibromyalgia and the aim of this study was to determine if such patients differ clinically from primary fibromyalgia patients with normal levels of procollagen type III aminoterminal peptide. Subjective symptoms, tender points and dynamic muscle strength in 45 women with primary fibromyalgia were related to serum concentrations of procollagen type III aminoterminal peptide. Patients with low serum concentrations of procollagen type III aminoterminal peptide had more symptoms, a higher frequency of tender points and lesser quality of sleep compared to patients with normal serum concentrations of procollagen type III aminoterminal peptide (P less than 0.05). They also had a lower dynamic muscle strength (P less than 0.0005). We conclude that the serum concentrations of procollagen type III aminoterminal peptide of primary fibromyalgia patients are connected to the disease impact.
KW - Adult
KW - Aged
KW - Female
KW - Fibromyalgia
KW - Humans
KW - Middle Aged
KW - Muscles
KW - Pain
KW - Peptide Fragments
KW - Procollagen
KW - Sleep Wake Disorders
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
M3 - Journal article
C2 - 2357497
VL - 29
SP - 174
EP - 177
JO - British Journal of Rheumatology
JF - British Journal of Rheumatology
SN - 0263-7103
IS - 3
ER -
ID: 168533529